BIO Form 4: 4,110 RSUs Vest, EVP Sells 277 Shares at $295.43

Rhea-AI Filing Summary

Evran Sedat, Executive Vice President, Global Supply Chain at Bio-Rad Laboratories (BIO), reported insider transactions on a Form 4 covering September 5–6, 2025. The filing shows vesting and purchases that increased his direct holdings and a small sale. Specifically, 4,110 restricted stock units vested on 09/05/2025 and were converted into 4,110 shares. On 09/06/2025 an additional 864 restricted stock units vested and were converted into 864 shares. The report also lists purchases under the Employee Stock Purchase Plan earlier in 2025 totaling 83.707 shares (56.9880 and 26.7190) and a disposition of 277 shares sold at $295.43.

The transactions are reported as direct holdings and reflect routine equity compensation vesting and periodic ESPP participation, with the sale reducing holdings by 277 shares to 1,523.847 shares following the reported sale.

Positive

• 4,110 restricted stock units vested and converted to shares on 09/05/2025, increasing direct ownership
• 864 restricted stock units vested and converted to shares on 09/06/2025, further increasing direct ownership
• Participation in ESPP with 56.9880 and 26.7190 shares acquired on 03/31/2025 and 06/30/2025 respectively, showing alignment with shareholder interests

Negative

• 277 shares were sold on 09/06/2025 at $295.43, reducing direct holdings to 1,523.847 shares

Insights

Corporate Governance Expert

TL;DR: Routine executive equity vesting and small ESPP purchases reported; a minor sale occurred, suggesting normal compensation liquidity.

The Form 4 documents standard equity compensation activity: time‑based restricted stock units vesting and conversions to common stock, plus small ESPP purchases earlier in the year. These are typical mechanisms to align executive incentives with shareholders. The single sale of 277 shares at $295.43 appears modest relative to total shares reported and is common for tax or diversification needs. No unusual derivative exercises or pledging are disclosed, and all holdings are reported as direct ownership.

Securities Analyst

TL;DR: Insider increased holdings through vesting and ESPP contributions, with a minor disposal; impact on valuation is immaterial.

From an investor‑impact perspective, the material elements are the conversion of 4,110 RSUs on 09/05/2025 and 864 RSUs on 09/06/2025 into common stock, increasing direct share count. ESPP purchases of 56.9880 and 26.7190 shares in March and June 2025 respectively show continued participation in the company plan. The sale of 277 shares at $295.43 reduced post‑transaction holdings to 1,523.847 shares. These moves are routine and not material to company capital structure or market supply.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EVRAN SEDAT

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Supply Chain

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		864(1)	A	$0	1,800.847(2)	D
Bio-Rad A Common Stock	09/06/2025		F		277	D	$295.43	1,523.847	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	09/05/2025		A		4,110		(4)	(4)	Bio-Rad A Common Stock	4,110	$0	4,110	D
Restricted Stock Units	$0(3)	09/06/2025		M			864	(4)	(4)	Bio-Rad A Common Stock	864	$0	2,592	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Includes 56.9880 and 26.7190 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2025 and 06/30/2025, respectively.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Sedat Evran	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BIO executive Evran Sedat report on Form 4?

The Form 4 reports the vesting and conversion of 4,110 RSUs on 09/05/2025 and 864 RSUs on 09/06/2025, ESPP purchases of 56.9880 and 26.7190 shares in 2025, and a sale of 277 shares at $295.43.

How many shares did Evran Sedat own after the reported transactions?

Following the reported sale, the filing shows Evran Sedat held 1,523.847 shares of Bio‑Rad Class A common stock.

Were the vested restricted stock units (RSUs) reported as direct or indirect ownership?

The RSUs that vested and converted to shares are reported as direct (D) ownership in the filing.

Did the Form 4 disclose any option exercises or derivative transactions?

No option exercises were disclosed; the Form 4 shows restricted stock units vesting and ESPP purchases but no derivative exercises.

What explanation does the filing provide about RSU vesting?

The filing states each RSU represents one share and that RSUs vest over four years at 25% per year on the anniversary of the grant.